Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: Clinical and tissue microarray based analysis

Journal of Surgical Oncology

Volumn 97, Issue 5, 2008, Pages 416-422

  Cohen, Tzeela ^a   Prus, Diana ^a   Shia, Jinru ^b   Abu Wasel, Bassam ^a   Pinto, Meir G ^a   Freund, Herbert R ^a   Stojadinovic, Alexander ^c   Grakov, Anna ^a   Peretz, Tamar ^a   Nissan, Aviram ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Colorectal neoplasms; Ki 67; Microarray; p21; p53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; KI 67 ANTIGEN; PARAFFIN; PROTEIN P27;

ADULT; ARAB; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ELECTIVE SURGERY; ETHNICITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JEW; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGE FACTORS; ARABS; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; JEWS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 41549166159     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20989     Document Type: Article

References (50)

1. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Weir HK, Thun MJ, Hankey BF, et al.: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-1299.
3. Barchana M, Liphshitz I, Rozen P: Trends in colorectal cancer incidence and mortality in the Israeli Jewish ethnic populations. Fam Cancer 2004;3:207-214.
4. Watson P, Lin KM, Rodriguez-Bigas MA, et al.: Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 1998;83:259-266.
5. Benatti P, Gafa R, Barana D, et al.: Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005;11:8332-8340.
6. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-944.
7. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
8. Vogelstein B, Fearon ER, Hamilton SR, et al.: Genetic alterations during colorectal-tumour development. N Engl J Med 1988;319: 525-532.
9. Baker SJ, Markowitz S, Fearon ER, et al.: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249:912-915.
10. Lowe SW, Schmitt EM, Smith SW, et al.: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362:847-849.
11. Hollstein M, Sidransky D, Vogelstein B, et al.: p53 mutations in human cancers. Science 1991;253:49-53.
12. Bosari S, Viale G, Roncalli M, et al.: p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995;147:790-798.
13. Soong R, Grieu F, Robbins P, et al.: p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 1997;3:1405-1411.
14. Ahnen DJ, Feigl P, Quan G, et al.: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study. Cancer Res 1998;58:1149-1158.
15. Kressner U, Inganas M, Byding S, et al.: Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999;17:593-599.
16. Belluco C, Guillem JG, Kemeny N, et al.: p53 nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 1996;14:2696-2701.
17. Leahy DT, Salman R, Mulcahy H, et al.: Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 1996;180:364-370.
18. Paradiso A, Simone G, Petroni S, et al.: Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000;82:560-567.
19. Samowitz WS, Curtin K, Ma KN, et al.: Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2002;99:597-602.
20. Soong R, Powell B, Elsaleh H, et al.: Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000;36:2053-2060.
21. Lee JM, Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993;90:5742-5746.
22. Yang B, Eshleman JR, Berger NA, et al.: Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 1996;2:1649-1657.
23. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
24. Pagano M, Tam SW, Theodoras AM, et al.: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685.
25. Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 1996;271:1861-1864.
26. Katayose Y, Kim M, Rakkar AN, et al.: Promoting apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997;57:5441-5445.
27. Fredersdorf S, Burns J, Milne AM, et al.: High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380-6385.
28. Galizia G, Lieto E, Ferraraccio F, et al.: Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004;10:3490-3499.
29. Loda M, Cukor B, Tam SW, et al.: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-234.
30. Liu DF, Ferguson K, Cooper GS, et al.: p27 cell-cycle inhibitor is inversely correlated with lymph node metastases in right-sided colon cancer. J Clin Lab Anal 1999;13:291-295.
31. Gerdes J, Schwab U, Lemke H, et al.: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;3:13-20.
32. Gerdes J, Lemke H, Baisch H, et al.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
33. Bouzubar N, Walker KJ, Griffiths K, et al.: Ki67 immunostaining in primary breast cancer: Pathological and clinical associations. Br J Cancer 1989;59:943-947.
34. Allegra CJ, Parr AL, Wold LE, et al.: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002;20:1735-1743.
35. Johnston PG, O'Brien MJ, Dervan PA, et al.: Immunohistochemical analysis of cell kinetic parameters in colonic adenocarcinomas, adenomas, and normal mucosa. Hum Pathol 1989;20:696-700.
36. Kyzer S, Gordon PH: Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki67. Dis Colon Rectum 1997;40:322-325.
37. McShane LM, Altman DG, Sauerbrei W, et al.: Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumour marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97: 1180-1184.
38. Hoos A, Cordon-Cardo C: Tissue microarray profiling of cancer specimens and cell lines: Opportunities and limitations. Lab Invest 2001;81:1331-1338.
39. Kononen J, Bubendorf L, Kallioniemi A, et al.: Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med 1998;4:844-847.
40. Compton CC, Fielding LP, Burgart LJ, et al.: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979-994.
41. Kornmann M, Schwabe W, Sander S, et al.: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA_expression levels: Predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-4124.
42. Fidder HH, Figer A, Geva R, et al.: Genetic analyses in consecutive israeli jewish colorectal cancer patients. Am J Gastroenterol 2005;100:1376-1380.
43. Bat L, Pines A, Ron E, et al.: Colorectal adenomatous polyps and carcinoma in Ashkenazi and non-Ashkenazi Jews in Israel. Cancer 1986;58:1167-1171.
44. Lynch HT, Rubinstein WS, Locker GY: Cancer in Jews: Introduction and overview. Fam Cancer 2004;3:177-192.
45. Torhorst J, Bucher C, Kononen J, et al.: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-2256.
46. Camp RL, Charette LA, Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-1949.
47. Hoos A, Nissan A, Stojadinovic A, et al.: Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: A comprehensive analysis. Clin Cancer Res 2002;8: 3841-3849.
48. Klump B, Nehls O, Okech T, et al.: Molecular lesions in colorectal cancer: Impact on prognosis? Original data and review of the literature. Int J Colorectal Dis 2004;19:23-42.
49. Loda M, Cukor B, Tam SW, et al.: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-234.
50. Tenjo T, Toyoda M, Okuda J, et al.: Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 2000;58: 45-51.